missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human DERL2 (aa 217-239) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (100%), Rat (100%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-61845 (PA5-61845. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Functional component of endoplasmic reticulum-associated degradation (ERAD) for misfolded lumenal glycoproteins, but not that of misfolded nonglycoproteins. May act by forming a channel that allows the retrotranslocation of misfolded glycoproteins into the cytosol where they are ubiquitinated and degraded by the proteasome. May mediate the interaction between VCP and the degradation substrate. In contrast to DERL1, it is not involved in the degradation of MHC class I heavy chains following infection by cytomegaloviruses. May play a role in cell proliferation.
Specifications
Specifications
| Accession Number | Q9GZP9 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 51009 |
| Name | Human DERL2 (aa 217-239) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | carcinoma related; CGI-101; Degradation in endoplasmic reticulum protein 2; Der1-like domain family, member 2; der1-like protein 2; Der2; Derl2; derlin 2; derlin-2; derlin-2-like; DERtrin-2; F-LAN-1; Flana; F-LANa; LOC100910823; SBBI53 |
| Common Name | DERL2 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction